Natural beta interferon in acute type-C hepatitis patients: a randomized controlled trial

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Acute hepatitis C is a significant public health concern.
• Identifying effective early treatments for hepatitis C is crucial to prevent chronic infection.
• Beta interferon has shown potential in modulating viral infections.

Purpose of the Study:

• To evaluate the efficacy of a short course of beta interferon in preventing the chronicity of acute hepatitis C.
• To assess the impact of beta interferon on the natural course of acute hepatitis C infection.

Main Methods:

• A multicentre randomized controlled trial involving 40 patients with acute hepatitis C.
• Patients received either natural beta interferon (3,000,000 IU IM thrice weekly for 4 weeks) or symptomatic treatment.
• Follow-up was conducted for a median of 22.5 months.

Main Results:

• The chronicity rate was 75% in the interferon group versus 80% in the untreated group, showing no significant difference.
• No significant difference was observed in the duration of the acute phase of hepatitis between the groups.
• Hepatitis C virus RNA remained detectable in most chronic cases at follow-up; side effects were mild and transient.

Conclusions:

• Beta interferon, administered at the tested regimen, is well-tolerated in patients with acute hepatitis C.
• The short course of beta interferon did not significantly influence the natural course or chronicity rate of acute hepatitis C.